Trinitrophenol

Trinitrophenol

SCHEMBL339139

CCCCOC(=O)c1ccc(N)cc1.O=[N+]([O-])c1cc([N+](=O)[O-])c(O)c([N+](=O)[O-])c1

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TRPA1TRPV4

The experimentally established mechanism targets of Trinitrophenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.64
CYP1A2 P05177 3/20 0.64
CYP3A4 P08684 2/20 0.64
TSHR P16473 2/20 0.64
CYP2C19 P33261 2/20 0.64
CYP2C9 P11712 1/20 0.64
PDE4D Q08499 1/20 0.64
ESR1 P03372 6/20 0.63
ALDH1A1 P00352 2/20 0.57
NPC1 O15118 2/20 0.57
MAPT P10636 1/20 0.57
RAB9A P51151 1/20 0.57
CYP2D6 P10635 2/20 0.53
CHRM2 P08172 1/20 0.53
HTR1A P08908 1/20 0.53
GAA P10253 1/20 0.53
DRD3 P35462 1/20 0.53
SCN1A P35498 1/20 0.53
SLC6A3 Q01959 1/20 0.53
KCNH2 Q12809 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trinitrophenol SCHEMBL339138 1.00 LMNA (0.64) LMNACYP1A2CYP3A4TSHRCYP2C19
Trinitrophenol SCHEMBL7554611 0.88 NPC1 (0.62) LMNACYP1A2CYP3A4ESR1ALDH1A1
Trinitrophenol SCHEMBL4189273 0.82 ALDH1A1 (0.65) LMNACYP3A4TSHRESR1ALDH1A1
SCHEMBL10946509 0.81 ESR1 (0.61) LMNACYP1A2CYP3A4TSHRCYP2C19
SCHEMBL3391559 0.80 PKM (0.66) LMNACYP1A2CYP3A4TSHRCYP2C19
Butamben SCHEMBL81735 0.80 LMNA (1.00) LMNACYP1A2CYP3A4TSHRCYP2C19
Butamben SCHEMBL27614630 0.78 LMNA (0.97) LMNACYP1A2CYP3A4TSHRCYP2C19
Butamben SCHEMBL28512544 0.78 LMNA (0.97) LMNACYP1A2CYP3A4TSHRCYP2C19
SCHEMBL11495159 0.78 ESR1 (0.57) LMNACYP1A2CYP3A4TSHRCYP2C19
SCHEMBL9762616 0.78 TDP1 (0.57) TSHRESR1ALDH1A1NPC1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210046040-A1 PAIN-RELIEVING TOPICAL COMPOSITIONS INNOCAN PHARMA LTD. (IL) 2021-02-18 US claimed
EP-3735225-A1 PAIN-RELIEVING TOPICAL COMPOSITIONS INNOCAN PHARMA LTD. (IL) 2020-11-11 EP claimed
WO-2020012480-A1 PAIN-RELIEVING TOPICAL COMPOSITIONS INNOCAN PHARMA LTD. (IL) 2020-01-16 WO claimed
US-20190224105-A9 COMPOUND, COMPOSITION, AND METHOD FOR PROTECTING SKIN FROM HIGH ENERGY VISIBLE LIGHT PHOTOPROTECTIVE TECHNOLOGIES, INC. (US) 2019-07-25 US claimed
US-20190008306-A1 COMPOUND, COMPOSITION, AND METHOD FOR PROTECTING SKIN FROM HIGH ENERGY VISIBLE LIGHT PHOTOPROTECTIVE TECH INC (US) 2019-01-10 US claimed
US-20180361032-A1 IMPLANTABLE ELECTROSPUN PATCHES FOR SITE-DIRECTED DRUG DELIVERY THE METHODIST HOSPITAL 2018-12-20 US claimed
US-20160317425-A1 COMPOUND, COMPOSITION, AND METHOD FOR PROTECTING SKIN FROM HIGH ENERGY VISIBLE LIGHT PHOTOPROTECTIVE TECHNOLOGIES, INC. (US) 2016-11-03 US claimed
US-20140348787-A1 Methods and Compositions for Treating Ear Infections PROFESSIONAL COMPOUNDING CENTERS OF AMERICA (US) 2014-11-27 US claimed
US-20140296826-A1 PREPARATION PATCH AND SAFETY SYRINGE SYSTEM COVIDIEN LP (US) 2014-10-02 US claimed
EP-2777719-A2 Preparation Patch and Safety Syringe System Covidien LP (US) 2014-09-17 EP claimed
CN-1058150-C Topical aromatic releasing compositions RICHARD VICKS INC (US) 2000-11-08 CN claimed
WO-2000041528-A2 IMPROVED CONTROLLED RELEASE COMPOSITIONS AND METHOD AMCOL INTERNATIONAL CORPORATION (US) 2000-07-20 WO claimed
WO-2000038617-A2 COMPOSITIONS AND METHODS OF USING THE SAME FOUR STAR PARTNERS (US) 2000-07-06 WO claimed
US-5814659-A ANALGESIC, ALCOHOL, CHAOTROPIC AGENT AND UNSATURATED FATTY ACID DTR DERMAL THERAPY (BARBADOS) INC. (BB) 1998-09-29 US claimed
EP-0727978-A4 TOPICAL AROMATIC RELEASING COMPOSITIONS RICHARDSON VICKS INC (US) 1997-01-29 EP claimed
EP-0727978-A1 TOPICAL AROMATIC RELEASING COMPOSITIONS RICHARDSON-VICKS, INC. (US) 1996-08-28 EP claimed
US-5322689-A Topical aromatic releasing compositions THE PROCTER & GAMBLE COMPANY (US) 1994-06-21 US claimed
CN-1079896-A The compositions of topical aromatic releasing RICHARDSON VICKS INC (US) 1993-12-29 CN claimed
WO-1993017655-A1 TOPICAL AROMATIC RELEASING COMPOSITIONS RICHARDSON VICKS INC. (US) 1993-09-16 WO claimed
US-4312865-A Medication having penetration through cutaneous surfaces into articular and muscular areas SZUCS MURRILL M 1982-01-26 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190224105-A9 COMPOUND, COMPOSITION, AND METHOD FOR PROTECTING SKIN FROM HIGH ENERGY VISIBLE LIGHT CUTA, TYR, XPA LMNA 549/4885CYP1A2 113/4885CYP3A4 268/4885
US-20160317425-A1 COMPOUND, COMPOSITION, AND METHOD FOR PROTECTING SKIN FROM HIGH ENERGY VISIBLE LIGHT CUTA, TYR, XPA LMNA 549/4885CYP1A2 113/4885CYP3A4 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.